Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10

Affiliations

¹ Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
² AstraZeneca Nordic-Baltic, Södertälje, Sweden johan.bodegard@astrazeneca.com.
³ Statisticon AB, Uppsala, Sweden.
⁴ Cardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
⁵ Capio S:t Görans Hospital, Stockholm, Sweden.
⁶ Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

Comment

Thomas Nyström et al. Diabetes Care. 2018 Jun.

. 2018 Jun;41(6):e104-e105.

doi: 10.2337/dc18-0339.

¹ Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
² AstraZeneca Nordic-Baltic, Södertälje, Sweden johan.bodegard@astrazeneca.com.
³ Statisticon AB, Uppsala, Sweden.
⁴ Cardiology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden.
⁵ Capio S:t Görans Hospital, Stockholm, Sweden.
⁶ Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

No abstract available

Comment in

Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Suissa S. Suissa S. Diabetes Care. 2018 Jun;41(6):e109-e110. doi: 10.2337/dci18-0015. Diabetes Care. 2018. PMID: 29784709 No abstract available.

Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
Suissa S. Suissa S. Diabetes Care. 2018 Jan;41(1):6-10. doi: 10.2337/dc17-1223. Diabetes Care. 2018. PMID: 29263192